Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.1.1.28 (
lactic acid dehydrogenase
)
476
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
S100beta
has been implicated in the formation of dystrophic neurites, overexpressing beta-amyloid precursor protein (betaAPP), in the beta-amyloid plaques of Alzheimer's disease. We assessed the effects of
S100beta
on cell viability of, neurite outgrowth from, and betaAPP expression by neurons in primary cultures from fetal rat cortex.
S100beta
(1-10 ng/ml) enhanced neuronal viability (as assessed by increased mitrochondrial activity and decreased
lactic acid dehydrogenase
release) and promoted neurite outgrowth. Higher levels of
S100beta
(100 ng/ml, but not 1 microg/ml) produced qualitatively similar, but less marked, effects.
S100beta
also induced increased neuronal expression of the microtubule-associated protein MAP2, an effect that is consistent with trophic effects of
S100beta
on neurite outgrowth.
S100beta
(10 and 100 ng/ml) induced graded increases in neuronal expression of betaAPP and of betaAPP mRNA. These results support our previous suggestion that excessive expression of
S100beta
by activated, plaque-associated astrocytes in Alzheimer's disease contributes to the appearance of dystrophic neurites overexpressing betaAPP in diffuse amyloid deposits, and thus to the conversion of these deposits into the diagnostic neuritic beta-amyloid plaques.
...
PMID:S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. 975 Nov 73
